The Venture Codex

Led · Series B · Aug 2026

Meduloc develops an FDA-cleared, sterile, single-use flexible nitinol intramedullary implant and delivery system for long-bone fracture applications in adult and pediatric patients. The platform is positioned to provide fracture stability while preserving anatomy and avoiding joint violation in certain applications. Following regulatory clearance, the company is moving into controlled commercialization and plans an alpha launch in early August 2026 with select surgeons and institutions to build clinical experience and collect feedback. Meduloc intends to use recently raised capital to generate additional clinical evidence and to build the commercial infrastructure required for broader adoption. The company is headquartered in West Chester, Pennsylvania, and has attracted regional investor support from Greater Philadelphia and statewide life-sciences funding organizations.

Participated · Series B · Oct 2025

DermaSensor’s core product is a wireless, handheld optical-spectroscopy device that assesses skin lesions at a cellular level, delivering automated skin-cancer detection for use in primary care settings. Cleared by the FDA via the De Novo pathway in early 2024, it is the only automated skin-cancer detection device available to U.S. primary-care physicians. Since its mid-2024 commercial launch, clinicians have scanned more than 20,000 lesions with the device, and usage is growing at an average quarterly rate of 117%. Published studies report sensitivity between 96-100% and specificity up to 77% for pigmented lesions, performance that has been highlighted in Nature and honored by TIME’s Best Inventions of 2024. The company’s AI training dataset has already grown several-fold beyond the original 2,000 lesions, and management cites approximately 2,000 suspicious cancers detected for referral to dermatology. Beyond the cleared algorithm, DermaSensor has three active pipeline programs that will run on the same hardware. To date the company has attracted $43 million in total investment, supporting both commercial expansion and additional clinical evidence generation.

Participated · Equity · Jun 2025

PreciseDx develops PreciseBreast, an AI-enabled diagnostic that uses the company’s OncoIntelligence platform to inform breast cancer care. PreciseBreast combines seven morphologic features and four clinical factors into a single OncoIntelligence Score (0–100) to stratify recurrence risk and support care planning within hours. The test has been clinically validated in more than 3,000 breast cancer cases to reliably separate patients into two cohorts based on six‑year recurrence risk. The company says the platform could extend to treatment guidance for other solid tumor types. PreciseDx announced an $11 million financing, bringing total funding to over $43 million, to support ongoing clinical data collection, commercial expansion and planning for a 2026 commercial launch. The company also announced two executive hires: Eric Converse as CEO and Ed Sitar as CFO; founder Carlos Cordon‑Cardo retains a financial interest. PreciseDx is an NYC-based innovator in oncology diagnostics that leverages artificial intelligence for morphology-driven disease analysis. Its platform combines AI with the patented Morphology Feature Array® (MFA) to generate actionable intelligence for decision-making across the cancer care continuum. The company's flagship offering is PreciseBreast™, a risk assessment intended to inform breast cancer care and screening decisions. PreciseDx plans to use new funding to expand commercialization of PreciseBreast™. Financially, PreciseDx recently closed a $20.7M Series B to support those commercialization efforts. The company has completed analytical and clinical validation studies, received CLIA Standard approval and CLEP NYSDOH review for PreciseBreast™, and had a Cost Impact Study published in the Journal of Medical Economics. PreciseDx has added collaborations with UCLA, COTA, Baptist Health South Florida, and Baylor Scott & White Health.

Participated · Series A · Aug 2024

Prana Thoracic develops the Prana System, an image-guided, minimally invasive platform designed to enable precision surgical solutions that conserve healthy tissue and support personalized treatment plans for lung cancer. The company targets earlier interventions for patients and says the system can be applied across a range of conditions including lung cancer. Prana is also exploring use of the technology in other soft tissues and investigating integration with ablation and robotic systems. Its team includes surgeons, engineers, and entrepreneurs and is led by CEO and co-founder Joanna Nathan. Financially, the company has raised $9 million to date—an initial $3M, a $3M non-dilutive grant, and a $3M Series A extension that was oversubscribed by 30%. The new funding will be used to accelerate product development and advance clinical and regulatory plans. Prana Thoracic is developing the ThoraCore System, a minimally invasive, lung-sparing tool designed to target hard-to-reach pulmonary nodules and enable definitive diagnosis earlier in the lung cancer care pathway. The company’s technology was developed on the Texas Medical Center campus in collaboration with Precision Thoracic Corporation and inventor Edward M. Boyle, MD. Prana is led by CEO and co-founder Joanna Nathan. The company announced the closing of a $3.0 million founding Series A financing and previously received a $3.0 million award from the Cancer Prevention & Research Institute of Texas. Proceeds from the Series A and the CPRIT award will be used for product development and to support first-in-human clinical studies. Prana positions the ThoraCore System to improve diagnostic access for patients with challenging lung nodules and accelerate earlier intervention. Prana Thoracic is developing a minimally invasive, tissue-sparing lung tissue excision tool intended to provide definitive diagnosis of suspicious pulmonary nodules earlier in the patient journey. The company says the device targets nodules that are challenging to sample, filling a gap between needle biopsy and open chest procedures. Prana Thoracic aims to commercialize the technology through first-in-human studies supported by the award. The company notes that lung cancer is the leading cause of cancer death in the U.S. and that screening rates are low despite large eligible populations. Prana Thoracic partnered with the Johnson & Johnson MedTech Center for Device Innovation for design and early testing. Joanna Nathan is CEO and founder, and Dr. Edward Boyle is a founder and one of the inventors of the technology.

Participated · Equity · Feb 2024

GeNeuro is a Geneva‑based clinical‑stage biopharmaceutical company developing temelimab, a monoclonal antibody that targets the HERV‑W Env protein implicated in MS and post‑COVID neuropsychiatric syndromes. The company has tested temelimab in over 200 patients for two years and reported consistent positive impacts across key MRI markers associated with disease progression. Its ongoing Phase 2 post‑COVID trial enrolled only patients positive for the pathogenic W‑ENV biomarker and completed recruitment in November 2023. Results from that trial are expected in June 2024, and the program has received Swiss and European support. GeNeuro is also in discussions to define combination strategies in multiple sclerosis (pairing anti‑inflammatory treatments with temelimab to address neurodegeneration). Financially, the company completed a capital increase to support the Phase 2 program and extend its runway, with proceeds expected to fund operations into the early third quarter of 2024. The new shares will be listed on Euronext Paris and carry immediate dividend and voting rights. GeNeuro develops first‑in‑class therapies against diseases associated with expression of pathogenic proteins of human endogenous retroviral origin (HERV), focusing on neurology and autoimmune disorders. Its lead product, GNbAC1, is a therapeutic antibody targeting the MSRV‑Env protein found in MS lesions; the antibody is intended to neutralize the protein's pro‑inflammatory and anti‑remyelination effects. The company has launched the Phase IIb CHANGE‑MS trial in relapsing‑remitting MS, planning to enroll 260 patients across 68 sites in the EU and Eastern Europe, with an initial endpoint analysis after six months and preliminary results expected by end of 2017. GeNeuro aims to develop GNbAC1 as a treatment for both relapsing‑remitting and progressive forms of MS without broadly suppressing the immune system. Through its partnership with Servier, the company has secured near‑term funding tied to clinical development and potential funding for global Phase III, improving its runway for pivotal studies. Founded in 2006 as an Eclosion/Institut Mérieux spin‑off, GeNeuro positions GNbAC1 as the first drug intended to address a potential causal factor of MS.